309 related articles for article (PubMed ID: 18441329)
1. Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
Puglisi F; Cardellino GG; Crivellari D; Di Loreto C; Magri MD; Minisini AM; Mansutti M; Andreetta C; Russo S; Lombardi D; Perin T; Damante G; Veronesi A
Ann Oncol; 2008 Sep; 19(9):1541-6. PubMed ID: 18441329
[TBL] [Abstract][Full Text] [Related]
2. Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer.
Andreetta C; Puppin C; Minisini A; Valent F; Pegolo E; Damante G; Di Loreto C; Pizzolitto S; Pandolfi M; Fasola G; Piga A; Puglisi F
Ann Oncol; 2009 Feb; 20(2):265-71. PubMed ID: 18765464
[TBL] [Abstract][Full Text] [Related]
3. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
Mackey JR; Tonkin KS; Koski SL; Scarfe AG; Smylie MG; Joy AA; Au HJ; Bodnar DM; Soulieres D; Smith SW
Clin Breast Cancer; 2004 Oct; 5(4):287-92. PubMed ID: 15507175
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer.
Vaishampayan UN; Marur S; Heilbrun LK; Cher ML; Dickow B; Smith DW; Al Hasan SA; Eliason J
J Urol; 2009 Jul; 182(1):317-23. PubMed ID: 19447430
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of docetaxel combined capecitabine on metastatic breast cancer].
Wang XX; Zhou ZM; Yuan ZY; Zhang DS; Shi YX; Jiang WQ
Ai Zheng; 2007 Apr; 26(4):407-10. PubMed ID: 17430662
[TBL] [Abstract][Full Text] [Related]
6. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
Wang Z; Lu J; Leaw S; Hong X; Wang J; Shao Z; Hu X
Cancer Chemother Pharmacol; 2012 Feb; 69(2):515-22. PubMed ID: 21874317
[TBL] [Abstract][Full Text] [Related]
7. A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer.
Bayo J; Lomas M; Salvador J; Moreno A; Ruiz M; Rodríguez A; Fuentes J; Fernández-Freire A; Bernabé R; Fernández A
Clin Transl Oncol; 2008 Dec; 10(12):817-25. PubMed ID: 19068453
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer.
Layman RM; Thomas DG; Griffith KA; Smerage JB; Helvie MA; Roubidoux MA; Diehl KM; Newman LA; Sabel MS; Hayman JA; Pierce LJ; Hayes DF; Schott AF
Clin Cancer Res; 2007 Jul; 13(14):4092-7. PubMed ID: 17634534
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.
Ernst T; Merx K; Gnad-Vogt U; Lukan N; Kripp M; Schultheis B; Hochhaus A; Hofheinz RD
Br J Cancer; 2007 Dec; 97(11):1475-9. PubMed ID: 18000507
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
[TBL] [Abstract][Full Text] [Related]
11. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
O'Shaughnessy J; Miles D; Vukelja S; Moiseyenko V; Ayoub JP; Cervantes G; Fumoleau P; Jones S; Lui WY; Mauriac L; Twelves C; Van Hazel G; Verma S; Leonard R
J Clin Oncol; 2002 Jun; 20(12):2812-23. PubMed ID: 12065558
[TBL] [Abstract][Full Text] [Related]
12. Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer.
Han JY; Hong EK; Lee SY; Yoon SM; Lee DH; Lee JS
J Clin Pathol; 2005 Jun; 58(6):650-4. PubMed ID: 15917420
[TBL] [Abstract][Full Text] [Related]
13. Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies.
Nadella P; Shapiro C; Otterson GA; Hauger M; Erdal S; Kraut E; Clinton S; Shah M; Stanek M; Monk P; Villalona-Calero MA
J Clin Oncol; 2002 Jun; 20(11):2616-23. PubMed ID: 12039922
[TBL] [Abstract][Full Text] [Related]
14. A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer.
Silva O; Lopes G; Morgenzstern D; Lobo C; Doliny P; Santos E; Abdullah S; Gautam U; Reis I; Welsh C; Slingerland J; Hurley J; Gluck S
Clin Breast Cancer; 2008 Apr; 8(2):162-7. PubMed ID: 18621613
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer.
Jinno H; Sakata M; Hayashida T; Takahashi M; Mukai M; Ikeda T; Kitagawa Y
Ann Oncol; 2010 Jun; 21(6):1262-1266. PubMed ID: 19854722
[TBL] [Abstract][Full Text] [Related]
16. Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study.
Rosati G; Bilancia D; Germano D; Dinota A; Romano R; Reggiardo G; Manzione L
Ann Oncol; 2007 Jun; 18 Suppl 6():vi128-32. PubMed ID: 17591806
[TBL] [Abstract][Full Text] [Related]
17. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?
Leonard R; O'Shaughnessy J; Vukelja S; Gorbounova V; Chan-Navarro CA; Maraninchi D; Barak-Wigler N; McKendrick JJ; Harker WG; Bexon AS; Twelves C
Ann Oncol; 2006 Sep; 17(9):1379-85. PubMed ID: 16966367
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
Michalaki V; Fotiou S; Gennatas S; Gennatas C
Anticancer Res; 2010 Jul; 30(7):3051-4. PubMed ID: 20683054
[TBL] [Abstract][Full Text] [Related]
19. [Docetaxel and capecitabine combination chemotherapy for patients with anthracycline-resistant metastatic breast cancer].
Li SF; Wang X; Wang C; He LH; Shi YH; Hao CF; Dong GL; Tong ZS
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):944-6. PubMed ID: 19174000
[TBL] [Abstract][Full Text] [Related]
20. North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer.
Perez EA; Hillman DW; Dentchev T; Le-Lindqwister NA; Geeraerts LH; Fitch TR; Liu H; Graham DL; Kahanic SP; Gross HM; Patel TA; Palmieri FM; Dueck AC
Ann Oncol; 2010 Feb; 21(2):269-274. PubMed ID: 19901014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]